OncLive® Scientific Interchange and Workshop Podcast Series: Management of HER2+ Breast Cancer

In the first segment, Dr Gradishar and colleagues examine the unmet needs clinicians face despite recent advances in the treatment of patients with HER2-positive breast cancer.

Dr Gradishar and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Dr Gradishar and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

In the first segment, Dr Mahtani and colleagues outline challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

In the second segment, Dr Mahtani and colleagues discuss data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Dr Mahtani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Dr Pegram and colleagues focus on key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.